Sucralfate
Loading...Sucralfate Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Sucralfate tablets, USP are indicated in:
- Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
- Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
History
There is currently no drug history available for this drug.
Other Information
Sucralfate, USP is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex.
Tablets for oral administration contain 1 g of sucralfate, USP and the following inactive ingredients: corn starch, magnesium stearate, and microcrystalline cellulose.
Therapeutic Category
antiulcer
FOR COMPLETE INFORMATION ON THIS DRUG, PLEASE VIEW THE MANUFACTURER'S SITE:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7a43df7-eb37-4273-9250-87953b1fd270
Sources
Sucralfate Manufacturers
- Northwind Pharmaceuticals, Llc
![Sucralfate Tablet [Northwind Pharmaceuticals, Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Sucralfate | Northwind Pharmaceuticals, Llc
Active Duodenal Ulcer
The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy
The recommended adult oral dosage is 1 g twice a day.
Elderly
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Nostrum Laboratories, Inc.
Sucralfate | Blenheim Pharmacal, Inc.
General Principles:
The goal of replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state. The goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. The dose of Levothyroxine Sodium Tablets, USP that is adequate to achieve these goals depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature of the condition being treated (see WARNINGS and PRECAUTIONS). Hence, the following recommendations serve only as dosing guidelines. Dosing must be individualized and adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters (see PRECAUTIONS, Laboratory Tests).
Levothyroxine Sodium Tablets, USP should be taken in the morning on an empty stomach, at least one-half hour to one hour before any food is eaten. Levothyroxine Sodium Tablets, USP should be taken at least 4 hours apart from drugs that are known to interfere with its absorption (see PRECAUTIONS, Drug Interactions).
Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks.
Caution should be exercised when administering Levothyroxine Sodium Tablets, USP to patients with underlying cardiovascular disease, to the elderly, and to those with concomitant adrenal insufficiency (see PRECAUTIONS).
Specific Patient Populations:
Hypothyroidism in Adults and in Children in Whom Growth and Puberty are Complete (see WARNINGS and PRECAUTIONS, Laboratory Tests).
Therapy may begin at full replacement doses in otherwise healthy individuals less than 50 years old and in those older than 50 years who have been recently treated for hyperthyroidism or who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of levothyroxine sodium is approximately 1.7 mcg/kg/day (e.g., 100-125 mcg/day for a 70 kg adult). Older patients may require less than 1 mcg/kg/day. Levothyroxine sodium doses greater than 200 mcg/day are seldom required. An inadequate response to daily doses ≥ 300 mcg/day is rare and may indicate poor compliance, malabsorption, and/or drug interactions.
For most patients older than 50 years or for patients under 50 years of age with underlying cardiac disease, an initial starting dose of 25-50 mcg/day of levothyroxine sodium is recommended, with gradual increments in dose at 6-8 week intervals, as needed. The recommended starting dose of levothyroxine sodium in elderly patients with cardiac disease is 12.5-25 mcg/day, with gradual dose increments at 4-6 week intervals. The levothyroxine sodium dose is generally adjusted in 12.5-25 mcg increments until the patient with primary hypothyroidism is clinically euthyroid and the serum TSH has normalized.
In patients with severe hypothyroidism, the recommended initial levothyroxine sodium dose is 12.5-25 mcg/day with increases of 25 mcg/day every 2-4 weeks, accompanied by clinical and laboratory assessment, until the TSH level is normalized.
In patients with secondary (pituitary) or tertiary (hypothalamic) hypothyroidism, the levothyroxine sodium dose should be titrated until the patient is clinically euthyroid and the serum free-T 4 level is restored to the upper half of the normal range.
Pediatric Dosage - Congenital or Acquired Hypothyroidism (see PRECAUTIONS, Laboratory Tests)
General Principles
In general, levothyroxine therapy should be instituted at full replacement doses as soon as possible. Delays in diagnosis and institution of therapy may have deleterious effects on the child's intellectual and physical growth and development.
Undertreatment and overtreatment should be avoided (see PRECAUTIONS, Pediatric Use).
Levothyroxine Sodium Tablets, USP may be administered to infants and children who cannot swallow intact tablets by crushing the tablet and suspending the freshly crushed tablet in a small amount (5-10 mL or 1-2 teaspoons) of water. This suspension can be administered by spoon or dropper. DO NOT STORE THE SUSPENSION. Foods that decrease absorption of levothyroxine, such as soybean infant formula, should not be used for administering levothyroxine sodium tablets. (see PRECAUTIONS, Drug-Food Interactions).
Newborns
The recommended starting dose of levothyroxine sodium in newborn infants is 10-15 mcg/kg/day. A lower starting dose (e.g., 25 mcg/day) should be considered in infants at risk for cardiac failure, and the dose should be increased in 4-6 weeks as needed based on clinical and laboratory response to treatment. In infants with very low (< 5 mcg/dL) or undetectable serum T 4 concentrations, the recommended initial starting dose is 50 mcg/day of levothyroxine sodium.
Infants and Children
Levothyroxine therapy is usually initiated at full replacement doses, with the recommended dose per body weight decreasing with age (see TABLE 3). However, in children with chronic or severe hypothyroidism, an initial dose of 25 mcg/day of levothyroxine sodium is recommended with increments of 25 mcg every 2-4 weeks until the desired effect is achieved.
Hyperactivity in an older child can be minimized if the starting dose is one-fourth of the recommended full replacement dose, and the dose is then increased on a weekly basis by an amount equal to one-fourth the full-recommended replacement dose until the full recommended replacement dose is reached.
Table 3: Levothyroxine Sodium Dosing Guidelines for Pediatric Hypothyroidism a. The dose should be adjusted based on clinical response and laboratory parameters (see PRECAUTlONS, Laboratory Tests and Pediatric Use). AGE Daily Dose Per Kg Body Weighta 0-3 months 10-15 mcg/kg/day 3-6 months 8-10 mcg/kg/day 6-12 months 6-8 mcg/kg/day 1-5 years 5-6 mcg/kg/day 6-12 years 4-5 mcg/kg/day >12 years but growth and puberty incomplete 2-3 mcg/kg/day Growth and puberty complete 1.7 mcg/kg/dayPregnancy- Pregnancy may increase levothyroxine requirements (see PREGNANCY).
Subclinical Hypothyroidism- If this condition is treated, a lower levothyroxine sodium dose (e.g., 1 mcg/kg/day) than that used for full replacement may be adequate to normalize the serum TSH level. Patients who are not treated should be monitored yearly for changes in clinical status and thyroid laboratory parameters.
TSH Suppression in Well-differentiated Thyroid Cancer and Thyroid Nodules- The target level for TSH suppression in these conditions has not been established with controlled studies. In addition, the efficacy of TSH suppression for benign nodular disease is controversial. Therefore, the dose of Levothyroxine Sodium Tablets, USP used for TSH suppression should be individualized based on the specific disease and the patient being treated.
In the treatment of well differentiated (papillary and follicular) thyroid cancer, levothyroxine is used as an adjunct to surgery and radioiodine therapy. Generally, TSH is suppressed to <0.1 mU/L, and this usually requires a levothyroxine sodium dose of greater than 2 mcg/kg/day. However, in patients with high-risk tumors, the target level for TSH suppression may be <0.01 mU/L.
In the treatment of benign nodules and nontoxic multinodular goiter, TSH is generally suppressed to a higher target (e.g., 0.1-0.5 mU/L for nodules and 0.5-1.0 mU/L for multinodular goiter) than that used for the treatment of thyroid cancer. Levothyroxine sodium is contraindicated if the serum TSH is already suppressed due to the risk of precipitating overt thyrotoxicosis (see CONTRAINDICATIONS, WARNINGS and PRECAUTIONS).
Myxedema Coma - Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Therefore, oral thyroid hormone drug products are not recommended to treat this condition. Thyroid hormone products formulated for intravenous administration should be administered.
- Levista, Inc.
Sucralfate | Levista, Inc.
Active Duodenal Ulcer: The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day.
Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS Geriatric Use )
- Stat Rx Usa Llc
Sucralfate |
- State Of Florida Doh Central Pharmacy
Sucralfate | State Of Florida Doh Central Pharmacy
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- State Of Florida Doh Central Pharmacy
Sucralfate | State Of Florida Doh Central Pharmacy
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- Watson Laboratories, Inc.
Sucralfate | Watson Laboratories, Inc.
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times a day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy. The recommended adult oral dosage is 1 g twice a day.
- Cardinal Health
Sucralfate | Cardinal Health
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- Udl Laboratories, Inc.
Sucralfate | Udl Laboratories, Inc.
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- Remedyrepack Inc.
Sucralfate | Remedyrepack Inc.
DOSAGE AND ADMINISTRATION Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- Remedyrepack Inc.
Sucralfate | Remedyrepack Inc.
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times a day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy. The recommended adult oral dosage is 1 g twice a day. - Golden State Medical Supply, Inc.
Sucralfate | Golden State Medical Supply, Inc.
Active Duodenal Ulcer: The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day.
Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS Geriatric Use )
- Pd-rx Pharmaceuticals, Inc.
Sucralfate | Pd-rx Pharmaceuticals, Inc.
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times a day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy. The recommended adult oral dosage is 1 g twice a day.
- Mckesson Contract Packaging
Sucralfate | Mckesson Contract Packaging
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- American Health Packaging
Sucralfate | Dava Pharmaceuticals, Inc.
DOSAGE MUST BE INDIVIDUALIZED. The initial dosage of doxazosin mesylate tablets in patients with hypertension and/or BPH is 1 mg given once daily in the a.m. or p.m. This starting dose is intended to minimize the frequency of postural hypotension and first dose syncope associated with doxazosin mesylate tablets. Postural effects are most likely to occur between 2 and 6 hours after a dose. Therefore blood pressure measurements should be taken during this time period after the first dose and with each increase in dose. If doxazosin mesylate tablets administration is discontinued for several days, therapy should be restarted using the initial dosing regimen.
Concomitant administration of doxazosin mesylate with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking doxazosin mesylate tablets.
A. BENIGN PROSTATIC HYPERPLASIA 1-8 mg once daily. The initial dosage of doxazosin mesylate tablets is 1 mg, given once daily in the a.m. or p.m. Depending on the individual patient’s urodynamics and BPH symptomatology, dosage may then be increased to 2 mg and thereafter to 4 mg and 8 mg once daily, the maximum recommended dose for BPH. The recommended titration interval is 1-2 weeks. Blood pressure should be evaluated routinely in these patients.
B. HYPERTENSION 1-16 mg once daily. The initial dosage of doxazosin mesylate tablets is 1 mg given once daily. Depending on the individual patient’s standing blood pressure response (based on measurements taken at 2-6 hours post-dose and 24 hours post-dose), dosage may then be increased to 2 mg and thereafter if necessary to 4 mg, 8 mg and 16 mg to achieve the desired reduction in blood pressure. Increases in dose beyond 4 mg increase the likelihood of excessive postural effects including syncope, postural dizziness/vertigo and postural hypotension. At a titrated dose of 16 mg once daily the frequency of postural effects is about 12% compared to 3% for placebo.
- Teva Pharmaceuticals Usa Inc
Sucralfate | Teva Pharmaceuticals Usa Inc
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Lake Erie Medical Dba Quality Care Products Llc
Sucralfate | Lake Erie Medical Dba Quality Care Products Llc
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Ncs Healthcare Of Ky, Inc Dba Vangard Labs
Sucralfate | Secan Pharmaceuticals Inc.
2.1 AdultsThe usual initial antihypertensive oral dose of amlodipine is 5 mg once daily, and the a maximum dose is 10 mg once daily.
Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other antihypertensive therapy.
Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently.
Angina: The recommended dose for chronic stable or vasospastic angina is 5 to10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect.
Coronary artery disease: The recommended dose range for patients with coronary artery disease is 5 to10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4)].
2.2 ChildrenThe effective antihypertensive oral dose in pediatric patients ages 6 - 17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients [see Clinical Pharmacology (12.4), Clinical Studies (14.1)].
- Cardinal Health
Sucralfate | Cardinal Health
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.)
- Avkare, Inc.
Sucralfate | Avkare, Inc.
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to AvKARE Customer Response Line at 1-855-361-3993 or drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Aphena Pharma Solutions – Tennessee, Llc
Sucralfate | Aphena Pharma Solutions - Tennessee, Llc
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times a day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy. The recommended adult oral dosage is 1 g twice a day.
- Mylan Institutional Inc.
Sucralfate | Mylan Institutional Inc.
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Bryant Ranch Prepack
Sucralfate | Bryant Ranch Prepack
- Cardinal Health
Sucralfate | Cardinal Health
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Medsource Pharmaceuticals
Sucralfate | Medsource Pharmaceuticals
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Preferred Pharmaceuticals Inc.
Sucralfate | Preferred Pharmaceuticals Inc.
Active Duodenal UlcerThe recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.
Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance TherapyThe recommended adult oral dosage is 1 g twice a day.
ElderlyIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS, Geriatric Use).
Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
![Sucralfate Tablet [Nostrum Laboratories, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f547137-d471-15f6-e054-00144ff8d46c&name=LABEL_LEVOTHYROXINESODIUMTABS0-025MG_BPI(10544-247-30)_LANNETT(0527-1341-10)_REV2-Copy.jpg)
![Sucralfate Tablet [Levista, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f6d7a9a8-dec5-4439-9c21-08b14d0a41b1&name=100-cnt.jpg)
![Sucralfate Tablet [Stat Rx Usa Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7e61193-6f73-4ae6-9560-ff23003b959b&name=SUCRALFATE_1GM_LABEL.jpg)
![Sucralfate Tablet [State Of Florida Doh Central Pharmacy]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04e60cc5-bdce-4b76-9ec4-3c531fec081d&name=Sucralfate1gm(Teva).jpg)
![Sucralfate Tablet [State Of Florida Doh Central Pharmacy]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c48dda77-c4a6-4241-91dd-2cef599b0833&name=Sucralfate1gm(Watson).jpg)
![Sucralfate Tablet [Watson Laboratories, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62819787-beb7-408a-9e23-a61b4720e99c&name=sucralfate-tablets-2.jpg)
![Sucralfate Tablet [Cardinal Health]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8ba7933f-169e-42d4-8dfe-736f38070f29&name=8ba7933f-169e-42d4-8dfe-736f38070f29-02.jpg)
![Sucralfate Tablet [Udl Laboratories, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e03f716-32c8-4173-99d8-ae8826d9d043&name=1e03f716-32c8-4173-99d8-ae8826d9d043-02.jpg)
![Sucralfate (Sucralfate) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f8ea3dc2-6142-444c-9aba-14158a7a43bb&name=CARD.jpg)
![Sucralfate Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d82013c-b952-40b8-9dd5-4dffc5911928&name=MM2.jpg)
![Sucralfate Tablet [Golden State Medical Supply, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c0320d58-a947-451e-96fb-7c9d5ef92bf4&name=c0320d58-a947-451e-96fb-7c9d5ef92bf4-02.jpg)
![Sucralfate Tablet [Pd-rx Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47b60d73-2abe-4fe5-a8bb-826b5a86ca27&name=55289292.jpg)
![Sucralfate Tablet [Mckesson Contract Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2bde09da-d053-447e-84e5-a3cc29abd91b&name=2bde09da-d053-447e-84e5-a3cc29abd91b-02.jpg)
![Sucralfate Tablet [American Health Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4abe1804-ae5f-4401-b84c-8ca6a71fbf74&name=doxazosin--5.jpg)
![Sucralfate Tablet [Teva Pharmaceuticals Usa Inc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7a43df7-eb37-4273-9250-87953b1fd270&name=4db8cb98-4335-464d-a3f1-1045f5e6f86b-02.jpg)
![Sucralfate Tablet [Lake Erie Medical Dba Quality Care Products Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37e55705-2804-4826-b2e7-80b486ebb981&name=Sucralfate1gPliva.jpg)
![Sucralfate Tablet [Ncs Healthcare Of Ky, Inc Dba Vangard Labs]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009&name=04392bd3-ee68-4cdc-82c0-41df1d096c93-04.jpg)
![Sucralfate Tablet [Cardinal Health]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e37d6f6c-e7b7-4285-9991-3152c0d6e192&name=e7d1eb47-8e82-4d07-b7b3-e7c33509aab8-02.jpg)
![Sucralfate (Sucralfate) Tablet [Avkare, Inc.]](http://recallguide.cwdevelopsp.com/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
![Sucralfate Tablet [Aphena Pharma Solutions – Tennessee, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=636edacc-ff9a-41c2-9903-14cf28b935a7&name=43353-061.jpg)
![Sucralfate Tablet [Mylan Institutional Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=989ca8a8-3ad6-4ee4-aa9c-eed731828753&name=image-01.jpg)
![Sucralfate Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2687d670-8af6-42a2-9081-fee112e80fc0&name=label1datamaxfda176.jpg)
![Sucralfate Tablet [Cardinal Health]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=444a743a-4843-4b33-bad5-3dfc1fb2d004&name=image-01.jpg)
![Sucralfate Tablet [Medsource Pharmaceuticals]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=209b629d-e460-61b1-e054-00144ff8d46c&name=845-49.jpg)
![Sucralfate Tablet [Preferred Pharmaceuticals Inc.]](https://www.recallguide.org/wp-content/themes/bootstrap/assets/img/drug-image-placeholder.jpg)
Login To Your Free Account